DSGN Earnings Prediction
The chart below shows how DSGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DSGN sees a -4.82% change in stock price 10 days leading up to the earnings, and a -6.78% change 10 days following the report. On the earnings day itself, the stock moves by -0.68%. This data can give you a slight idea of what to expect for the next quarter's release.
DSGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.21
-32.26%
-25.00%
No Data Available
DSGN Earnings Analysis
Design Therapeutics, Inc. Corporation (DSGN.O) Earnings Conference Call
Positive
- Design Therapeutics has discovered a new class of small molecules that can dial up or down the expression of individual genes in the genome, targeting monogenic disorders where the single gene causing the disease is known, such as Friedreich Ataxia, Fuchs Endothelial Corneal Dystrophy, Huntington’s Disease, and Myotonic Dystrophy.
- The company's GeneTAC small molecules platform has the potential to surpass competing modalities like gene editing and gene therapy for the treatment of monogenic diseases, offering first or best in class profiles with substantial market opportunities.
- Design Therapeutics has successfully taken their lead molecule DT216 for Friedreich Ataxia into clinical trials, confirming its ability to increase the level of frataxin RNA expression in patients with FA, and has developed a new drug product DT-216P2 with a more sustained exposure profile to advance further into development.
- The company has received FDA clearance to proceed with Phase 1 development for their FECD program with DT-168, aiming to initiate trials in 2024, and has also announced their Huntington’s Disease program aiming to identify and advance molecules with allele-selective reduction of Mutant Huntington expression.
- Point** Design Therapeutics has a significant cash runway of approximately $281 million, providing a five-year operating runway to generate clinical proof of concept data in up to four programs, demonstrating a strong financial position to support their research and development efforts.
Negative
- The company faced limitations with the prior formulation of DT-216 in human studies, leading to challenges in drug exposure and drug levels in plasma, which hindered progress in clinical development.
- Injection site thrombophlebitis events observed with the prior product candidate restricted dosing levels and frequency, highlighting formulation issues that required resolution.
- Despite advancements with a new drug product, DT-216P2, there were concerns about the tolerability and frequency of dosing, as well as the need to confirm pharmacokinetics and injection site tolerability in Phase 1 trials.
- The company's FECD program faced delays due to the necessity to conduct an observational study before proceeding with investigational drug treatment trials, indicating a slower-than-expected progression in clinical development.
